BioGenex
48810 Kato Road, Suite 100E & 200E, Fremont, CA 94538
Tel : +1 (800) 421-4149, Fax: +1 (510) 824-1490,
support@biogenex.com

DATA SHEET
Hsa-miR-141Probe

Catalog No.	Description
HM141-100	One vial of 0.650 ml of probe in hybridization buffer

Analyte Specific Reagent. Analytical and performance characteristics are not established.

Doc. No. 932-HM141-100 Rev : D
Date of release: 12-Aug-2020

Description
The Hsa-miR-141 probe has been designed from mature human miR-141 sequence. This fluoresceinated probe is provided in a hybridization buffer for localization of miRNA in FFPE tissue by *In Situ* hybridization.

Specifications
The Hsa-miR-141 identifies mature miR-141 sequences in formalin-fixed, paraffin-embedded human tissues and/or freshly prepared frozen tissues by *in situ* hybridization. This probe does not react with normal human mRNA or nuclear DNA present in tissues.

Storage and Handling
Store the reagent at 2-8 °C. Do not freeze. Do not use the reagent after expiration date on vial. The reagent must be brought to room temperature before use. (Important! The presence of precipitates induces background staining).

Precautions:
For professional use. The probe contains formamide. Formamide is classified as a teratogen. Pregnant workers should keep exposure to a minimum. Avoid inhalation, ingestion, and contact with unprotected skin. If skin contact occurs, wash thoroughly with soap and water. For more information, refer to the Material Safety Data Sheet, which is available upon request.

Quality Control
Each lot of this micro RNA probe is tested by *In Situ* hybridization for Quality Control purposes. Refer to the BioGenex Quality Control Testing Conditions table for additional information.

References

1. Lorio MV and Croce CM. (2012). MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review.**EMBO Mol Med** 4, 143–159.

2. Chen PS, Su JL, and Hung MC. (2012). Dysregulation of Micro RNAs in cancer. **Journal of Biomedical Science**, 19:90.

3. Nuovo GJ. (2008). In situ detection of precursor and mature microRNAs in paraffin embedded, formalin fixed tissues and cell preparations. **Methods** 44,39–46.

4. Song R. et al. (2010). In situ hybridization detection of microRNAs.**Methods Mol Biol**. 629, 287-94.

BioGenex
48810 Kato Road, Suite 100E & 200E, Fremont, CA 94538
Tel : +1 (800) 421-4149, Fax: +1 (510) 824-1490,
support@biogenex.com

5. Hyun S, Lee JH, Jin H, Nam J, Namkoong B, Lee G et al. (2009). Conserved MicroRNA miR-8/miR-200 and its target USH/FOG2 control growth by regulating PI3K.". **Cell** 139 (6), 1096–108.

6. HarpreetKaurSaini, Sam Griffiths-Jones, and Anton James Enright (2007).Genomic analysis of human microRNA transcripts **PNAS 1**04 (45), 17719–17724.

7. Park, S.-M., Gaur, A. B., Lengyel, E., Peter, M. E. Evaluated expression of 207 miRNAs in 60 human cell lines and found that expression of miR200 family members, including miR141, was associated with an epithelial phenotype.

8. Mateescu, B., Batista, L., Cardon, M., Gruosso, T., de Feraudy, Y., et al. (2011). miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. **Nature Med.** 17, 1627-1635,

9. Park, S.-M., Gaur, A. B., Lengyel, E., Peter, M. E. (2009). The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. **Genes Dev.** 22, 894-907, 2008. Note: Erratum: Genes Dev. 23: 1378.

BioGenex Quality Control Testing Conditions

Parameter	Conditions used
Control Tissue	TCC, PROSTATE (FB-HM141).
Tissue Type	Formalin-fixed, paraffin-embedded cancer tissues